Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.68 |
| ▸ | BUB1 | O43683 | 1/20 | 0.68 |
| ▸ | PRKACG | P22612 | 1/20 | 0.68 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.68 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.68 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269612 | 0.91 | MAPK14 (0.67) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269606 | 0.91 | MAPK14 (0.67) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269617 | 0.91 | MAPK14 (0.66) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269518 | 0.90 | MAPK14 (0.65) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269604 | 0.89 | MAPK14 (0.62) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL13715064 | 0.89 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269522 | 0.89 | MAPK14 (0.64) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269650 | 0.88 | MAPK14 (0.60) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL4887694 | 0.88 | MAPK14 (0.61) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL14269614 | 0.87 | MAPK14 (0.62) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | claimed |
| EP-1805132-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006110173-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-19 | — | — | WO | claimed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| EP-1805132-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006110173-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051416-A1 | Novel Compounds | MAPK1, MAPKAPK2, MAPK6 | MAPK14 23/4885CYP2C9 2102/4885MAPK11 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.